We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Reducing Septic Shock Hyperglycemia with Hydrocortisone

By HospiMedica staff writers
Posted on 06 Mar 2007
Continuous infusion of low-dose hydrocortisone reduces hyperglycemia more easily in patients with septic shock, according to a new study.

Researchers from the Päijät-Häme Central Hospital (Lahti, Finland), Kuopio University Hospital (Kuopio, Finland), and colleagues from other hospitals throughout Finland carried out a randomized controlled clinical trial involving 48 patients in four intensive care units (ICUs) between July 2005 and April 2006. More...
One group of 24 patients received the hydrocortisone treatment by continuous infusion of 200 mg/day. The bolus therapy group of 24 patients received the same overall dose, but the hydrocortisone was administered intravenously in 50 mg doses every six hours. Hydrocortisone treatment lasted five days in both groups. The researchers compared blood glucose levels, insulin requirements, and the nursing workload for the two groups.

The researchers found that the mean blood glucose levels were similar in both groups, but the number of hyperglycemic episodes was higher in the group receiving bolus therapy. For patients undergoing bolus therapy, the insulin infusion rate had to be changed more often to maintain normal blood glucose levels, adding to nurses' workload. The researchers stressed, however, that normal blood glucose levels can be achieved successfully using both methods. The study was published in the January 2007 issue of the journal Critical Care.

"Our findings suggest that, in septic shock, strict normoglycemia is more easily achieved with continuous hydrocortisone infusion. However, the differences between the study groups were rather marginal, and in both groups the normoglycemic goal could be achieved quite successfully. This approach also reduces nursing workload needed to maintain tight blood glucose control,” concluded lead author Dr. Pekka Loisa, from the department of intensive care at Päijät-Häme Central Hospital.


Related Links:
Kuopio University Hospital

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.